Key result
Heart-infiltrating prominin-1+ progenitors are the major source of TGF-β-triggered cardiac fibrosis, with >60% of cardiac fibroblasts deriving from bone marrow in experimental autoimmune myocarditis.
Why the study?
Does anti-TGF-β antibody treatment prevent myocardial fibrosis in a mouse model of experimental autoimmune myocarditis?
Does anti-TGF-β antibody treatment prevent myocardial fibrosis in a mouse model of experimental autoimmune myocarditis?
Heart-infiltrating prominin-1+ progenitor cells are the major source of TGF-β-mediated cardiac fibrosis in experimental autoimmune myocarditis, and anti-TGF-β treatment prevents this fibrosis.
Suggests TGF-β blockade may limit fibrosis in myocarditis models; leaves open clinical translation and human outcomes.
Rationale : Myocardial fibrosis is a hallmark of inflammation-triggered end-stage heart disease, a common cause of heart failure in young patients. Objective : We used CD4 + T-cell–mediated experimental autoimmune myocarditis model to determine the parameters regulating cardiac fibrosis in inflammatory heart disease. Methods and Results : α-Myosin heavy chain peptide/complete Freund’s adjuvant immunization was used to induce experimental autoimmune myocarditis in BALB/c mice. Chimeric mice, reconstituted with enhanced green fluorescence protein (EGFP) + bone marrow, were used to track the fate of inflammatory cells. Prominin-1 + cells were isolated from the inflamed hearts, cultured in vitro and injected intracardially at different stages of experimental autoimmune myocarditis. Transforming growth factor (TGF)-β–mediated fibrosis was addressed using anti–TGF-β antibody treatment. Myocarditis peaked 21 days after immunization and numbers of cardiac fibroblasts progressively increased on follow-up. In chimeric mice, >60% of cardiac fibroblasts were EGFP + 46 days after immunization. At day 21, cardiac infiltrates contained ≈30% of prominin-1 + progenitors. In vitro and in vivo experiments confirmed that prominin-1 + but not prominin-1 − cells isolated from acutely inflamed hearts represented the cellular source of cardiac fibroblasts at late stages of disease, characterized by increased TGF-β levels within the myocardium. Mechanistically, the in vitro differentiation of heart-infiltrating prominin-1 + cells into fibroblasts depended on TGF-β–mediated phosphorylation of Smad proteins. Accordingly, anti–TGF-β antibody treatment prevented myocardial fibrosis in immunized mice. Conclusions : Taken together, heart-infiltrating prominin-1 + progenitors are the major source of subsequent TGF-β–triggered cardiac fibrosis in experimental autoimmune myocarditis. Recognizing the critical, cytokine-dependent role of bone marrow–derived progenitors in cardiac remodeling might result in novel treatment concepts against inflammatory heart failure.
No takes yet. Share an insight, caveat, or question.
Kania et al. (2009) studied Experimental autoimmune myocarditis. anti-TGF-β antibody treatment was evaluated on Myocardial fibrosis and cellular source of cardiac fibroblasts. Heart-infiltrating prominin-1+ progenitors are the major source of TGF-β-triggered cardiac fibrosis, with >60% of cardiac fibroblasts deriving from bone marrow in experimental autoimmune myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: